If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLegal & General Regulatory News (LGEN)

Share Price Information for Legal & General (LGEN)

Share Price is delayed by 15 minutes
Get Live Data
295.40    2.30 (0.78%)
Bid:
295.40
Ask:
295.50
Spread: 0.10 (0.034%)
Market Cap: £16.17b
LGEN Live PriceLast checked at - London Stock Exchange

Intraday Legal & General Share Chart

Stabilisation Notice

30 Jun 2026 08:56

RNS Number : 3609K
J.P. Morgan Securities PLC.
30 June 2026
 

30th June 2026

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Legal & General Group PLC

 

Pre-stabilisation Period Announcement

 

J.P. Morgan Securities PLC, (contact: Robert Chambers +442071342468) hereby gives notice, as Stabilisation Coordinator, that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Delegated Regulation EU/xxx/2016 under the Market Abuse Regulation (EU/596/2016).

The securities:

Issuer:

Legal & General Group PLC

Obligor (if any):

N/A

Aggregate nominal amount:

GBP Benchmark

Description:

GBP PerpNC7, RT1, Fixed, Unsecured, Subordinated

 

Listing: London Stock Exchange's International Securities Market

Offer price:

TBC

Other offer terms:

GBP 200k x 1k

Stabilisation: Relevant Stabilisation regulation applies 

Stabilisation Manager(s):

J.P. Morgan Securities PLC (Stabilisation coordinator)

Barclays (Stabilisation manager)

BNP Paribas (Stabilisation manager)

BOFA Securities (Stabilisation manager)

Citibank (Stabilisation manager)

HSBC (Stabilisation manager)

Santander (Stabilisation manager)

Stabilisation period expected to start on:

30th June 2026

Stabilisation period expected to end no later than:

30th July 2026

Existence, maximum size and conditions of use of overallotment facility:

The Stabilisation Manager(s) may over-allot the securities in an amount not exceeding 5% of the aggregate nominal amount stated above.

Stabilisation trading venue:

Over the counter, TBC

 

In connection with the offer of the above securities, the Stabilising Manager(s), or persons acting on behalf of the Stabilising Manager(s) may over-allot the securities, provided that the aggregate principal amount of the securities allotted does not exceed 105 percent of the aggregate principal amount of the securities, or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur and any stabilisation action, if begun, may cease at any time, but it must end no later than the earlier of 30 days after the issue date of the securities and 60 days after the date of allotment of the securities.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within Article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that in that Member State

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STAEAXKEDSLKEEA
Date   Source Headline
7th May 20256:00 pmRNSTransaction in Own Shares
6th May 20256:00 pmRNSTransaction in Own Shares
2nd May 20256:15 pmRNSTransaction in Own Shares
2nd May 20256:15 pmRNSDirector/PDMR Shareholding
1st May 20256:15 pmRNSTransaction in Own Shares
1st May 20256:15 pmRNSTotal Voting Rights
1st May 20256:15 pmRNSDirector/PDMR Shareholding
1st May 20256:15 pmRNSDirector/PDMR Shareholding
30th Apr 20256:00 pmRNSTransaction in Own Shares
29th Apr 20256:00 pmRNSTransaction in Own Shares
28th Apr 20256:00 pmRNSTransaction in Own Shares
25th Apr 20256:00 pmRNSTransaction in Own Shares
24th Apr 20256:15 pmRNSTransaction in Own Shares
24th Apr 20256:15 pmRNSDirector/PDMR Shareholding
23rd Apr 20256:15 pmRNSTransaction in Own Shares
22nd Apr 20255:45 pmRNSTransaction in Own Shares
17th Apr 20255:45 pmRNSTransaction in Own Shares
17th Apr 202511:59 amRNSHolding(s) in Company
15th Apr 20255:45 pmRNSTransaction in Own Shares
11th Apr 20256:00 pmRNSTransaction in Own Shares
10th Apr 20256:15 pmRNSDirector/PDMR Shareholding
10th Apr 202510:00 amRNSNotice of AGM
9th Apr 20256:00 pmRNSTransaction in Own Shares
8th Apr 20256:15 pmRNSDirector/PDMR Shareholding
8th Apr 20256:00 pmRNSTransaction in Own Shares
7th Apr 20256:15 pmRNSTransaction in Own Shares
7th Apr 20256:15 pmRNSDirector/PDMR Shareholding
7th Apr 20256:15 pmRNSHolding(s) in Company
4th Apr 20256:00 pmRNSTransaction in Own Shares
4th Apr 20259:00 amRNSMajor Shareholding Notification
3rd Apr 20256:15 pmRNSTransaction in Own Shares
2nd Apr 20256:15 pmRNSTransaction in Own Shares
2nd Apr 20256:15 pmRNSDirector/PDMR Shareholding
2nd Apr 202511:00 amRNSTender Offer - Final Results
1st Apr 20256:15 pmRNSTransaction in Own Shares
1st Apr 20256:15 pmRNSDirector/PDMR Shareholding
1st Apr 20256:15 pmRNSTotal Voting Rights
1st Apr 20256:15 pmRNSDirector/PDMR Shareholding
31st Mar 20256:15 pmRNSTransaction in Own Shares
31st Mar 20256:15 pmRNSDirector/PDMR Shareholding
28th Mar 20256:00 pmRNSTransaction in Own Shares
28th Mar 202511:00 amRNSPublication of Final Terms
27th Mar 20256:15 pmRNSTransaction in Own Shares
26th Mar 20256:00 pmRNSTransaction in Own Shares
26th Mar 20257:00 amRNSTender Offer - Maximum Acceptance Amount
25th Mar 20256:15 pmRNSTransaction in Own Shares
25th Mar 20259:00 amRNSTender Offer
24th Mar 20256:15 pmRNSTransaction in Own Shares
21st Mar 20256:15 pmRNSTransaction in Own Shares
21st Mar 20256:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.